TPR and cancer: It appears reasonable to assume that the unique and multifold anticancer activities we observed in our co-culture experiments with EpCAM-ReTARGTPRIFNαR149A are in part attributable to the pleiotropic and possibly mutually reinforcing biological activities of its IFNαR149A domain towards the targeted cancer cells as well as the engaged TPR-specific CD8pos T cells.